Contract drug developer AMRI will close down its Syracuse, NY, facility by midyear, part of an effort to cut costs and realign its business.
Pacira Pharmaceuticals is counting on an expanded indication and swell in demand for its surgical pain treatment, and the biotech has inked a deal with contract manufacturer Patheon to collaborate on production in a multiyear agreement.
One of three manufacturing sites commissioned by the Department of Health and Human Services to quickly develop and produce flu vaccines in the case of a pandemic is expected to be fully operational by 2017, officials say.
To help countries achieve the maximum impact of new vaccines, the World Health Organization has released new guidance on how to introduce new vaccines in existing immunization programs.
Contract developer Particle Sciences has nailed down a deal with Actavis, lending its drug delivery expertise to the generics giant.
WuXi PharmaTech, China's largest pharma outsourcing outfit, is investing in a startup that makes tiny, edible bar codes designed to prevent drug counterfeiting, planning to offer the same technology to its manufacturing customers.
At the start of 2014 the Chinese vaccine sector was rocked by the failure of three leading suppliers to obtain good manufacturing practice certification. Sinovac Biotech escaped unscathed from the rule tightening and this week posted a 17% jump in fourth-quarter sales.
AMRI has inked a deal to trade $41 million for contract manufacturer Cedarburg Pharmaceuticals, looking to broaden its capabilities in the sector and home in on API production.
Indian CRO GVK Biosciences is looking to boost its capabilities in contract manufacturing, planning to build a new plant in its home country while stretching its presence abroad.
A $2.6 billion deal united contract manufacturers Patheon and DSM Pharmaceutical Products, and now the combined company has emerged to do business under the monicker DPx, expecting to bank $2 billion in revenue this year.